Literature DB >> 30487643

De novo truncating variants in PHF21A cause intellectual disability and craniofacial anomalies.

Kohei Hamanaka1, Yuji Sugawara2, Takeyoshi Shimoji3, Tone Irene Nordtveit4, Mitsuhiro Kato5, Mitsuko Nakashima6, Hirotomo Saitsu6, Toshimitsu Suzuki7, Kazuhiro Yamakawa7, Ingvild Aukrust4, Gunnar Houge4, Satomi Mitsuhashi1, Atsushi Takata1, Kazuhiro Iwama1, Ahmed Alkanaq1, Atsushi Fujita1, Eri Imagawa1, Takeshi Mizuguchi1, Noriko Miyake1, Satoko Miyatake1,8, Naomichi Matsumoto9.   

Abstract

Potocki-Shaffer syndrome (PSS) is a contiguous gene syndrome caused by 11p11.2 deletions. PSS is clinically characterized by intellectual disability, craniofacial anomalies, enlarged parietal foramina, and multiple exostoses. PSS occasionally shows autism spectrum disorder, epilepsy, and overgrowth. Some of the clinical features are thought to be associated with haploinsufficiency of two genes in the 11p11.2 region; variants affecting the function of ALX4 cause enlarged parietal foramina and EXT2 lead to multiple exostoses. However, the remaining clinical features were still yet to be linked to specific genetic alterations. In this study, we identified de novo truncating variants in an 11p11.2 gene, PHF21A, in three cases with intellectual disability and craniofacial anomalies. Among these three cases, autism spectrum disorder was recognized in one case, epilepsy in one case, and overgrowth in two cases. This study shows that PHF21A haploinsufficiency results in intellectual disability and craniofacial anomalies and possibly contributes to susceptibility to autism spectrum disorder, epilepsy, and overgrowth, all of which are PSS features.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30487643      PMCID: PMC6460561          DOI: 10.1038/s41431-018-0289-x

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  20 in total

1.  Translocations disrupting PHF21A in the Potocki-Shaffer-syndrome region are associated with intellectual disability and craniofacial anomalies.

Authors:  Hyung-Goo Kim; Hyun-Taek Kim; Natalia T Leach; Fei Lan; Reinhard Ullmann; Asli Silahtaroglu; Ingo Kurth; Anja Nowka; Ihn Sik Seong; Yiping Shen; Michael E Talkowski; Douglas Ruderfer; Ji-Hyun Lee; Caron Glotzbach; Kyungsoo Ha; Susanne Kjaergaard; Alex V Levin; Bernd F Romeike; Tjitske Kleefstra; Oliver Bartsch; Sarah H Elsea; Ethylin Wang Jabs; Marcy E MacDonald; David J Harris; Bradley J Quade; Hans-Hilger Ropers; Lisa G Shaffer; Kerstin Kutsche; Lawrence C Layman; Niels Tommerup; Vera M Kalscheuer; Yang Shi; Cynthia C Morton; Cheol-Hee Kim; James F Gusella
Journal:  Am J Hum Genet       Date:  2012-07-05       Impact factor: 11.025

2.  Interstitial deletion 11(p11.12p11.2) and analphoid marker formation results in inherited Potocki-Shaffer syndrome.

Authors:  Louise Chuang; Keiko Wakui; Whey-Chen Sue; Mei-Hsu Su; Lisa G Shaffer; Pao-Lin Kuo
Journal:  Am J Med Genet A       Date:  2005-03-01       Impact factor: 2.802

Review 3.  Potocki-Shaffer syndrome: comprehensive clinical assessment, review of the literature, and proposals for medical management.

Authors:  Daniel T Swarr; Douglas Bloom; Richard Alan Lewis; Ewa Elenberg; Ellen M Friedman; Caron Glotzbach; Scott D Wissman; Lisa G Shaffer; Lorraine Potocki
Journal:  Am J Med Genet A       Date:  2010-03       Impact factor: 2.802

4.  Role of the cyclic AMP response element binding complex and activation of mitogen-activated protein kinases in synergistic activation of the glycoprotein hormone alpha subunit gene by epidermal growth factor and forskolin.

Authors:  M S Roberson; M Ban; T Zhang; J M Mulvaney
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

5.  Delayed Diagnosis of Potocki-Shaffer Syndrome in a Woman with Multiple Exostoses and Mental Retardation.

Authors:  C Palka; M Alfonsi; A Mohn; P Guanciali Franchi; F Chiarelli; G Calabrese
Journal:  Mol Syndromol       Date:  2012-04-27

6.  A 137-kb deletion within the Potocki-Shaffer syndrome interval on chromosome 11p11.2 associated with developmental delay and hypotonia.

Authors:  Nathan D Montgomery; Christie M Turcott; James H Tepperberg; Marie T McDonald; Arthur S Aylsworth
Journal:  Am J Med Genet A       Date:  2012-12-13       Impact factor: 2.802

7.  Construction of a natural panel of 11p11.2 deletions and further delineation of the critical region involved in Potocki-Shaffer syndrome.

Authors:  Keiko Wakui; Giuliana Gregato; Blake C Ballif; Caron D Glotzbach; Kristen A Bailey; Pao-Lin Kuo; Whui-Chen Sue; Leslie J Sheffield; Mira Irons; Enrique G Gomez; Jacqueline T Hecht; Lorraine Potocki; Lisa G Shaffer
Journal:  Eur J Hum Genet       Date:  2005-05       Impact factor: 4.246

8.  Haploinsufficiency of ALX4 as a potential cause of parietal foramina in the 11p11.2 contiguous gene-deletion syndrome.

Authors:  Y Q Wu; J L Badano; C McCaskill; H Vogel; L Potocki; L G Shaffer
Journal:  Am J Hum Genet       Date:  2000-10-03       Impact factor: 11.025

Review 9.  Proximal chromosome 11p contiguous gene deletion syndrome phenotype: case report and review of the literature.

Authors:  B F M Romeike; W Wuyts
Journal:  Clin Neuropathol       Date:  2007 Jan-Feb       Impact factor: 1.368

Review 10.  Proximal 11p deletion syndrome (P11pDS): additional evaluation of the clinical and molecular aspects.

Authors:  Wim Wuyts; Gerard Waeber; Peter Meinecke; Herdit Schüler; Timm O Goecke; Wim Van Hul; Oliver Bartsch
Journal:  Eur J Hum Genet       Date:  2004-05       Impact factor: 4.246

View more
  6 in total

1.  Novel Pathogenic Variant (c.1171A>T) in PHF21A in a Female with Intellectual Disability and Craniofacial Anomalies.

Authors:  Cheonghwa Lee; Jung Yoon; Borae G Park; Baik-Lin Eun; Jung Ah Kwon
Journal:  Mol Syndromol       Date:  2022-03-09

2.  Disruption of PHF21A causes syndromic intellectual disability with craniofacial anomalies, epilepsy, hypotonia, and neurobehavioral problems including autism.

Authors:  Hyung-Goo Kim; Jill A Rosenfeld; Daryl A Scott; Gerard Bénédicte; Jonathan D Labonne; Jason Brown; Marianne McGuire; Sonal Mahida; Sakkubai Naidu; Jacqueline Gutierrez; Gaetan Lesca; Vincent des Portes; Ange-Line Bruel; Arthur Sorlin; Fan Xia; Yline Capri; Eric Muller; Dianalee McKnight; Erin Torti; Franz Rüschendorf; Oliver Hummel; Zeyaul Islam; Prasanna R Kolatkar; Lawrence C Layman; Duchwan Ryu; Il-Keun Kong; Suneeta Madan-Khetarpal; Cheol-Hee Kim
Journal:  Mol Autism       Date:  2019-10-22       Impact factor: 7.509

3.  11p11.12p12 duplication in a family with intellectual disability and craniofacial anomalies.

Authors:  Xuejiao Chen; Huihui Xu; Weiwu Shi; Feng Wang; Fenfen Xu; Yang Zhang; Jun Gan; Xiong Tian; Baojun Chen; Meizhen Dai
Journal:  BMC Med Genomics       Date:  2021-04-09       Impact factor: 3.063

4.  Bridging between Mouse and Human Enhancer-Promoter Long-Range Interactions in Neural Stem Cells, to Understand Enhancer Function in Neurodevelopmental Disease.

Authors:  Romina D'Aurizio; Orazio Catona; Mattia Pitasi; Yang Eric Li; Bing Ren; Silvia Kirsten Nicolis
Journal:  Int J Mol Sci       Date:  2022-07-19       Impact factor: 6.208

5.  The epigenetic reader PHF21B modulates murine social memory and synaptic plasticity-related genes.

Authors:  Eunice Wm Chin; Qi Ma; Hongyu Ruan; Camille Chin; Aditya Somasundaram; Chunling Zhang; Chunyu Liu; Martin D Lewis; Melissa White; Tracey L Smith; Malcolm Battersby; Wei-Dong Yao; Xin-Yun Lu; Wadih Arap; Julio Licinio; Ma-Li Wong
Journal:  JCI Insight       Date:  2022-07-22

6.  A recurrent PJA1 variant in trigonocephaly and neurodevelopmental disorders.

Authors:  Toshimitsu Suzuki; Toshifumi Suzuki; Matthieu Raveau; Noriko Miyake; Genki Sudo; Yoshinori Tsurusaki; Takaki Watanabe; Yuki Sugaya; Tetsuya Tatsukawa; Emi Mazaki; Atsushi Shimohata; Itaru Kushima; Branko Aleksic; Tomoko Shiino; Tomoko Toyota; Yoshimi Iwayama; Kentaro Nakaoka; Iori Ohmori; Aya Sasaki; Ken Watanabe; Shinichi Hirose; Sunao Kaneko; Yushi Inoue; Takeo Yoshikawa; Norio Ozaki; Masanobu Kano; Takeyoshi Shimoji; Naomichi Matsumoto; Kazuhiro Yamakawa
Journal:  Ann Clin Transl Neurol       Date:  2020-06-12       Impact factor: 4.511

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.